Cocrystal Pharma, Inc. cash flow to debt ratio of -544.32% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Cocrystal Pharma, Inc.'s free cash flow has increased -50.26% from $-16.49M last year to $-8.20M, signaling increasing performance

Cocrystal Pharma, Inc.'s debt to equity ratio is 0.35, which means that the company's assets are healthy financed, signaling financial stability.

Cocrystal Pharma, Inc.'s debt has increased relative to shareholder equity from 0.19 last year to 0.35 today, signaling weakened financials

Cocrystal Pharma, Inc. has a net cash position, so leverage is healthy.

Cocrystal Pharma, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Cocrystal Pharma, Inc. has insufficient data to evaluate this check.

Cocrystal Pharma, Inc.'s short-term assets of $8.13M exceed its short-term liabilities of $2.21M

Cocrystal Pharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Cocrystal Pharma, Inc.'s return on equity of -150.61%, is lower than 15.00%, indicating bad performance

Cocrystal Pharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Cocrystal Pharma, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Cocrystal Pharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Cocrystal Pharma, Inc. has negative free cash flow, indicating cash burn

Cocrystal Pharma, Inc.'s yearly earnings has increased -49.55% since last year from $-17.50M to $-8.83M, signaling increasing performance

Cocrystal Pharma, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -163.07% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Cocrystal Pharma, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Cocrystal Pharma, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Cocrystal Pharma, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Cocrystal Pharma, Inc. has insufficient data to evaluate this check.

Cocrystal Pharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cocrystal Pharma, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Cocrystal Pharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Cocrystal Pharma, Inc. has insufficient data to evaluate this check.

Cocrystal Pharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cocrystal Pharma, Inc. has a price-to-book ratio of 3.62x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Cocrystal Pharma, Inc. has a price-to-sales ratio of 66.26x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue